Targeting oncogenic and epigenetic survival pathways in lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2365-2376

  Leslie, Lori A ^a   Younes, Anas ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epigenetics; Lymphoma and Hodgkin disease; Oncogenic; Targeted therapies

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; BENDAMUSTINE; BROMODOMAIN INHIBITOR; EVEROLIMUS; FOSTAMATINIB; HISTONE DEACETYLASE INHIBITOR; IBRUTINIB; IDELALISIB; IPI 145; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PACRITINIB; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RITUXIMAB; STAT PROTEIN; TEMSIROLIMUS; TRANSCRIPTION FACTOR EZH2 INHIBITOR; UNCLASSIFIED DRUG; UO 126; VORINOSTAT;

B CELL LYMPHOMA; CANCER GROWTH; CELL SURVIVAL; CHROMATIN; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DRUG TARGETING; EPIGENETICS; FOLLICULAR LYMPHOMA; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TREATMENT OUTCOME;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; LYMPHOMA; ONCOGENE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84885656652     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.780288     Document Type: Review

References (91)

1. Fisher RI, Gaynor ER, Dahlberg 5, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin?s lymphoma. N Engi J Med 1993;328:1002-1006.
2. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83:301-311.
3. Turner M, Mee PJ, Costello PS, et al. Perinatal lethality and blocked B-Cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298-302.
4. Cheng AM, Rowley B, Pao W, et al. Syk tyrosine kinase required for mouse viability and B-Cell development. Nature 1995;378:303-306.
5. Abtahian F, Guerriero A, Sebzda E, et al. Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003;299:247-251.
6. Rolli Gallwitz M, Wossning T, et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell 2002;10:1057-1069.
7. Lam ICP, ICuhn R, Rajewsky K, In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073-1083.
8. Kraus M, Alimzhanov MB, Rajewsky N, et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004;117:787-800.
9. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-Cell lymphoma. Nature 2010;463:88-92.
10. Chen L, Juszczynski P, Takeyama IC, et al. Protein tyrosine phosphatase receptor-type 0 truncated (PTPROt) regulates SYIC phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 2006;108:3428-3433.
11. Chen LF, Monti 5, Juszczynski P, et al. SYIC-dependent tonic B-Cell receptor signaling is a rational treatment target in diffuse large B-Cell lymphoma. Blood 2008;111:2230-2237.
12. Braselmann 5, Taylor V, Zhao H, et al R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006;319:998-1008.
13. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;1 15:2578-2585.
14. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-Cell activation and is efficacious in models of autoimmune disease and B-Cell malignancy. Proc Natl Acad Sci USA 2010;107:13075-13080.
15. Herman SEM, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-6296.
16. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-Cell malignancies. J Clin Oncol 2013;31:88-94.
17. Wang LH, Martin P, Blum KA, et al. The Bruton?s tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): Preliminary results of a phase 11 trial. Blood 2011;118:203-204.
18. Byrd JC, Furman RR, Coutre SE, et al. The Bruton?s tyrosine kinase (BTIC) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase lb/Il study. J Clin Oncol 2012;30(SUPPL.): Abstract 6507.
19. Foster FM, Traer CT, Abraham SM, et al. The phosphoinositide (P1) 3-kinase family. J Cell Sci 2003;116:3037-3040.
20. WurmserAE, GaryJD, Emr SD, Phosphoinositide 3 -kinases and their FYVE domain-containing effectors as regulators of vacuolar/lysosomal membrane trafficking pathways. J Biol Chem 1999;274:9129-9132.
21. Volinia 5, Dhand R, Vanhaesebroeck B, et al. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-VpslSp protein sorting system. EMBO J 1995;14:3339-3348.
22. Zhou XA, Takatoh T, Wang F. The mammalian class 3 PI3IC (P11C3C3) is required for early embryogenesis and cell proliferation. PLoS One 2011;6:E 16358.
23. ICatso R, Okkenhaug IC, Ahmadi IC, et al. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-675.
24. Domin L Harper L, Aubyn D, et al. The class 11 phosphoinositide 3-kinase PI3IC-C2 beta regulates cell migration by a Ptdlns(3)P dependent mechanism. J Cell Physiol 2005;205:452-462.
25. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the P11C3CA gene in human cancers. Science 2004;304:554.
26. Bi L, Okabe I, Bernard DJ, et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p1 loalpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999;274:10963-10968.
27. Bi L, Okabe I, Bernard DJ, et al. Early embryonic lethality in mice deficient in the pliObeta catalytic subunit of P1 3-kinase Mamm. Genome 2002;13:169-172.
28. Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase pliOdelta in signaling by the B-Cell receptor complex. Mol Cell Biol 2002;22:8580-8591.
29. Vanhaesebroeck B, Ali IC, Bilancio A, et al. Signalling by PI3IC isoforms: Insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204.
30. Sasaki T, Irie-Sasaki J, Jones RG, et al. Function of PI3ICgamma in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040-1046.
31. Cai SL, Tee AR, Short JD, et al. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 2006;173:279-289.
32. Gingras AC, Kennedy SG, OLeary MA, et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998;12:502-513.
33. Reif IC, Okkenhaug IC, Sasaki T, et al. Cutting edge: Differential roles for phosphoinositide 3-kinases, pliOgamma and pliOdelta, in lymphocyte chemotaxis and homing. J Immunol 2004; 173:2236-2240.
34. Furman RR, Byrd JC, Flinn I, et al. Interim results from a phase 1 study of CAL-lOl, a selective oral inhibitor of phosphatidylinositol 3-kinase p1106 isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2010;28(15 Supplj: Abstract 3032.
35. Coutre 5, Byrd JC, Furman RR, et al. Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase PliOd, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2011;29(Supplj: Abstract 6631.
36. Leonard J, Schreeder M, Coutre 5, et al. A phase 1 study of Cal-lOl, an isoform-selective inhibitor of phosphatidylinositol 3-kinase PliOd, in combination with anti-CD2O monoclonal antibody therapy and/or bendamustine in patients with previously treated B-Cell malignancies. Ann Oncol 2011;22:137.
37. Webb LM, Vigorito E, Wymann MP, et al. Cutting edge: T cell development requires the combined activities of the pliOgamma and pliOdelta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005;175:2783-2787.
38. Swat W, Montgrain V, Doggett TA, et al. Essential role of PI3ICdelta and PI3ICgamma in thymocyte survival. Blood 2006;107:2415-2422.
39. Buglio D, Lemoine M, Estrella T, et al. The allosteric AKI inhibitor MIC-2206 demonstrates potent antiproliferative activity in lymphoma cells and synergizes with the HDAC inhibitor vorinostat. Blood 2011;118:1592-1593.
40. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008;113: 508-514.
41. Smith SM, Van Besien IC, ICarrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin?s lymphoma subtypes: The University of Chicago phase 11 consortium. J Clin Oncol 2010;28:4740-4746.
42. Hess G, Herbrecht R, Romaguera J, et al. Phase 11I study to evaluate temsirolimus compared with investigator?s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
43. Ansell SM, Tang H, ICurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 2011; 12:361-368.
44. Witzig E, Habermann T, Reeder C, et al. A phase 11 trial of the oral mTOR inhibitor everolimus in relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD). Presented at 14th Congress of the European Hematology Association, Berlin, Germany, 2009; Abstract 1081.
45. Witzig TE, Reeder CB, LaPlant BR, et al. A phase 11 trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011;25:341-347.
46. Johnston PB, Inwards DJ, Colgan JP, et al. A phase 11 trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am Hematol 2010;85:320-324.
47. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116: 2201-2207.
48. Johnston P, Pinter-Brown L, Rogerio J, et al. Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase 11 study. J Clin Oncol 2012;30(Supplj: Abstract 8028.
49. Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008;4:691-699.
50. Zhang YJ, Duan YW, Zheng XFS. Targeting the mTOR kinase domain: The second generation of mTOR inhibitors. Drug Discov Today 2011; 16:325-33 1.
51. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-298.
52. Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: Preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 2010;70:621-631.
53. Yu K, Toral-Barza L, Shi C, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 2009;69:6232-6240.
54. Lemoine M, Derenzini E, Buglio D, et al. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 2012;119: 4017-4025.
55. Younes A, Copeland A, Fanale M, et al. safety and efficacy of the novel combination ofpanobinostat (LBH589) and everolimus (RADOO1) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. Blood 2011;118(Supplj: Abstract 3718.
56. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-119.
57. Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-1RAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010;465:885-890.
58. Ding BB, Yu JJ, Yu RY, et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-Cell subtype of diffuse large B-Cell lymphomas. Blood 2008;1 11:1515-1523.
59. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappa B pathways in subtypes of diffuse large B-Cell lymphoma. Blood 2008;111:3701-3713.
60. Derenzini E, Lemoine M, Buglio D, et al. The JAK inhibitor AZD148O regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 2011;1:E46.
61. Younes A, Romaguera J, Fanale M, et al. Phase 1 study of a novel oral Janus kinase 2 inhibitor, 5B1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30:4161-4167.
62. PasqualucciL, Dominguez-SolaD, ChiarenzaA, etal.Inactivating mutations of acetyltransferase genes in B-Cell lymphoma. Nature 2011;471:189-195.
63. Kirschbaum M, Frankel P, Popplewell L, et al. Phase 11 study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin?s lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:1198-1203.
64. Ando K, Ogura M, Suzuki T, et al. A multicenter phase 11 study of vorinostat in patients (pts) with relapsed or refractory indolent B-Cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). Clin Oncol 2012;30(SUPPL.): Abstract 8029.
65. Crump M, Coiffier B, Jacobsen ED, et al. Phase 11 trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-Cell lymphoma. Ann Oncol 2008;19:964-969.
66. Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012;53: 259-262.
67. Younes A, Wedgewood A, McLaughlin P, et al. Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCDO1O3: Interim results from a phase 11 study. Blood 2007;110(Suppl. 1): Abstract 2571.
68. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin?s lymphoma: An open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-1228.
69. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin?s lymphoma after autologous stem-cell transplantation: Results of a phase 11 study. J Clin Oncol 2012;30:2197-2203.
70. Sparmann A, Van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846-856.
71. Jacobs JJL, Scheijen B, Voncken JW, et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-Induced apoptosis via INK4a/ARF. Genes Dev 1999; 13:2678-2690.
72. Haupt Y, Alexander WS, Barn G, et al. Novel zinc finger gene implicated as Myc collaborator by retrovirally accelerated lymphomagenesis in E-Mu-Myc transgenic mice. Cell 1991;65: 753-763.
73. Vanlohuizen M, Verbeek 5, Scheijen B, et al. Identification of cooperating oncogenes in E-Mu-Myc transgenic mice by provirus tagging. Cell 1991;65:737-752.
74. Van Kemenade FJ, Raaphorst FM, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-Cell non-Hodgkin lymphoma. Blood 2001;97:3896-3901.
75. Velichutina I, Shaknovich R, Geng HM, et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010;116:5247-5255.
76. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-Cell lymphomas of germinal-center origin. Nat Genet 2010;42:181-185.
77. Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011;6:E28585.
78. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011;117:2451-2459.
79. Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-Cell lymphomas. Proc Natl Acad Sci USA 2010;107:20980-20985.
80. Majer CR, Jin L, Scott MP, et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett 2012;19:3448-3451.
81. Chen SA, Bohrer LR, Rai AN, et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 2010;12:1108-1114.
82. Tang XH, Milyavsky M, Shats I, et al. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-5769.
83. McCabe MT, Graves AP, Ganji G, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-Cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 2012;109:2989-9294.
84. Fiskus W, Wang YC, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells Blood 2009;114:2733-2743.
85. Me ZG, Bi CL, Cheong LL, et al. Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells. PLoS One, 2011;6:E2 1583.
86. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009;8:1579-1588.
87. McCabe MI, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492:108-112.
88. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012;8:890-896.
89. Zuber L Shi JW, Wang E, et al. RNAI screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478: 524-528.
90. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 903-9 16.
91. Mertz JA, ConeryAR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011;108:16669-16674.